Gynecological cancer

The experimental cancer vaccine Tedopi (OSE2101), when given in combination with the approved injection therapy Keytruda (pembrolizumab), outperforms standard-of-care treatment in delaying disease…

A large clinical trial testing Merck’s therapy candidate sacituzumab tirumotecan (sac-TMT) in people with hard-to-treat endometrial cancer has achieved its main goal, with sac-TMT…

Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far in an early clinical trial,…

May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase awareness, support those affected, and…

The U.S. Food and Drug Administration (FDA) has granted fast track status to a combination of lunresertib and zedoresertib — two therapies in development by…

In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…

A new regimen using the immunotherapy Keytruda (pembrolizumab) has been approved in the European Union for use by certain people with hard-to-treat gynecological…

A test that uses artificial intelligence (AI) to analyze genetic data from a vaginal swab can detect endometrial cancer with high diagnostic accuracy, a new…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.

Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…